For instance, AR is starting to be recognized as attractive target in triple-negative (ER-/PR-/Her2-) breast cancer (55) and may be a critical target in other human malignancies in which sex differences exist in incidence and mortality, such as bladder cancer and hepatic cell carcinoma (56, 57). Here, ESR1 is linked to urinary bladder carcinoma.